Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
INCY
Home
/
INCY

NASDAQ
$122.85
$122.85

Overview

Price performance
Low
$117.52
High
$123.33
After hours. Last updated: Nov 4, 2026, 9:00 PM UTC
$
122.85
5.26 (4.47%)
Average, 50 days
$120.12
$108.19
Open
$117.52
Previous close
$117.59
52-week high
$132.60
Jul 28, 2026 (4 months ago)
52-week low
$89.25
Mar 24, 2026 (8 months ago)
37.65%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
25.04B
Volume
2 066 559
Total Return (3M)
1.87%
Total Return (1Y)
19.36%
27.21
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
Website
incyte.com
Socials
About
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.

Frequently asked questions

INCY · Incyte Corporation

01What is Incyte Corporation stock price today?

The current price of INCY is $122.85 — it has increased by 4.47% since the previous close. Data as of Nov 4, 2026.

02Is Incyte Corporation stock price growing?

INCY is up 2.29% over the past week, up 6.55% over the past month and up 19.36% over the past year. The price is above its 200-day moving average of $108.19.

03What is INCY stock forecast?

Analysts' average 12-month price target for INCY is $137.67, which implies 12.06% upside from the current price. Individual estimates range from $104.00 to $157.00.

04What do analysts say about INCY stock?

Of the 29 analysts covering Incyte Corporation, 2 rate it a strong buy, 11 rate it a buy, 14 rate it a hold, 1 rates it a sell and 1 rates it a strong sell. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.

05What is Incyte Corporation market cap?

Incyte Corporation has a market capitalization of $25.04B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

06What were Incyte Corporation earnings last quarter?

In its most recent quarterly report, Incyte Corporation posted a loss of $3.60 per share against an estimate of -$3.93, beating expectations by 8.40%. Upcoming reports are listed in the earnings calendar.

07What is Incyte Corporation revenue for the last quarter?

Incyte Corporation reported revenue of $1.56B in its most recent quarter, which has increased by 14.00% compared with the same quarter a year earlier. Analysts had expected $1.46B.

08Does Incyte Corporation pay dividends?

Incyte Corporation has not paid any dividends over the past year.

09Who are Incyte Corporation competitors?

Companies most comparable to Incyte Corporation include Regeneron Pharmaceuticals, Inc., Genmab A/S, Exelixis, Inc., Ligand Pharmaceuticals Incorporated and Legend Biotech Corporation.

10How volatile is INCY stock?

In the latest trading session INCY moved between $117.52 and $123.33, a range of 4.73% of its current price.

11Should I invest in Incyte Corporation stock?

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Incyte Corporation shows a strong buy rating today. Technical ratings are indicators, not investment advice.

12What are INCY stock 52-week high and low?

Over the past 52 weeks INCY has traded between $89.25 and $132.60. The current price is 7.35% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.